Quantcast

Latest Sipuleucel-T Stories

2010-05-10 16:33:00

SEATTLE, May 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009. The net loss for the quarter ended March 31, 2010 was $125.7 million, or $0.96 per share, compared to $15.4 million, or $0.16 per share for the quarter ended March 31, 2009. The losses for the quarters ended March 31, 2010 and 2009...

2010-05-05 10:18:00

SILVER SPRING, Md., May 5 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has approved a new treatment for certain men with advanced prostate cancer. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Called Provenge (sipuleucel-T), the treatment stimulates a patient's own immune system to respond against the cancer. Learn more about FDA's approval of Provenge at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm210620 Sign up for e-mail notices of new FDA...

2010-04-29 16:08:00

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA). Men's Health Network (MHN) is excited to see this innovative treatment option made available for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone...

2010-04-29 12:55:00

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in...

2010-04-29 12:08:00

SILVER SPRING, Md., April 29 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone...

2010-04-21 07:00:00

SEATTLE and WASHINGTON, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced the presentation of additional data from the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) clinical trial showing evidence of immune responses in patients treated with PROVENGE® (sipuleucel-T) and supporting its proposed mechanism of action. The data were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010...

2010-04-19 09:15:27

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona. "This study shows a potential new treatment paradigm in oncology and is the first active immunotherapy to demonstrate improvement in overall survival (OS) for metastatic CRPC...

2010-03-03 17:00:00

SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). The data will be presented at the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium...

2010-02-22 15:00:00

SEATTLE, Feb. 22 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2009. Revenue for the year ended December 31, 2009 was $101,000 compared to $111,000 for year ended December 31, 2008. Revenue for the fourth quarter of 2009 was $21,000 compared to $28,000 for the quarter ended December 31, 2008. The net loss for the year ended December 31, 2009 was $220.2 million, or $2.04 per share, compared to $71.6...

2009-12-11 17:13:00

SEATTLE, Dec. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 2,250,000 shares of common stock at the public offering price of $24.75 per share. The exercise of the option increases the size of the offering to an aggregate of 17,250,000 shares of common stock. Dendreon expects to receive net proceeds from the offering of...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related